Kornimate/medical-research-clean huggingface dataset:
huaier granule for prevention of disease progression of hepatocarcinoma after non-radical hepatectomy

Conditions: Hepatic Carcinoma

Summary: to evaluate the efficacy and safety of huaier granule for prevention of disease progression of hepatocarcinoma after non-radical hepatectomy.

a prospective, multicenter, open-labeled, parallel -controlled clinical study, to evaluate the efficacy and safety of huaier granule for prevention of disease progression of hepatocarcinoma after non-radical hepatectomy.

Eligibility criteria:
inclusion criteria: 1. age: ≥ 18 and ≤ 75 years, both male and female; 2. non-radical hepatectomy has been performed for hepatocellular carcinoma; 3. the hepatocellular carcinoma has been confirmed by pathological examination; 4. the liver and kidney function satisfies the following conditions within 15 days after surgery (excluding day 15): aspartate aminotransferase(ast), glutamic-oxalacetic transaminase(alt)\<3 upper limit of normal(uln), total bilirubin ≤2 uln, serum creatinine \<1.5 uln; 5. other laboratory tests meet the following requirements within 15 days after surgery (excluding day 15): hb≥9g/dl, platelet count≥60×109/l, neutrophil count\> 1.5×109/l; 6. the expected survival time ≥12 weeks; 7. the subjects volunteer to sign the informed consent. exclusion criteria: 1. non-hepatocellular carcinoma patients; 2. those who received radical hepatectomy; 3. those with hepatic decompensation; 4. pregnant or lactating women; 5. those with hiv infection or aids-associated diseases; 6. those with severe acute and chronic diseases, such as infection, diabetes cardiac insufficiency, pulmonary insufficiency, renal insufficiency; 7. those who can not take drugs by oral route; or those develop serious adverse drug reaction; 8. drug abusers or those with psychological or mental diseases that may interfere with study compliance; 9. conditions that are considered not suitable for this study investigators.

Keywords: huaier granule; after non-radical hepatectomy; prevention of disease progression of hepatocarcinoma; safety.
effects of postdilution online hemodiafiltration with acetate-free citrate dialysis fluid on inflammation markers

Conditions: ESRD

Summary: the aim of this study was to evaluate the effect and timing of action on the inflammatory state of a acetate-free containing citrate concentrate (cit-, 1 mm citrate) in online postidultion hdf with high volumes compared to traditional concentrated (ac-, 3 mm of acetate ) in the medium term. in addition, the study will evaluate other parameters of efficiency dialysis, cardiovascular stability, the safety of the concentrate with regard to bone metabolism and vessel calcification in the medium term.

the primary objective of this study was to evaluate if a hemodiafiltration with concentrated citrate (cit-hdf) in 3 months can reduce the inflammation markers, evaluated by a predialytic value of beta2-microglobulin (b2m), crp and il6 compared to traditional concentrated acetic acid (ac-hdf). the secondary objectives of this study are to evaluate if cit-hdf, compared to ac-hdf, can have an effect in a period of 3 months on the following aspects: * the change weekly pre-dialysis values of other markers of oxidative stress (tac, nf-kb); * the technical parameters of hdf treatment, such as convective volumes, and blood pressure in the circuit in the filter (tmp, pressure pre-filter); * the cardiovascular stability through blood pressure and heart rate before and after dialysis (sbp, dbp, hr) and number of intradialytic hypotension; * the parameters of safety as the variation of the values of the mobility predialytic bone (pth, alkaline phosphatase, fetuin-a), the variation of the values intradialytic biochemical impacted by citrate (total and ionized calcium, bicarbonate) and clotting time (aptt); * the variation of calcifications observed by: * the expression of molecules that express the ability of calcification of muscle cells and endothelial cells in culture with plasma taken at the beginning of treatment * a measure of carotid intimal thickness and pulse vawe velocity by eco color doppler (optional); * dialysis efficiency by varying pre-and post-dialysis (rr%) and clearance average molecular weight solutes with small and medium (phosphorus, beta2 micro, myoglobin) and indices of dialysis adequacy of small molecules such as ekt / v based on the dialysance ion formula watson (calculated automatically by the monitor to dialysis);

Eligibility criteria:
inclusion criteria: . patients clinically stable. * age\> 18. * hdf in renal replacement therapy for more than 1 month. * good functionality of the vascular blood flow that allows real at least 250 ml / min. and recirculation below 10%. exclusion criteria: * life expectancy \<3 months. * with residual renal function\> 500 ml / day. * vascular access with cvc

Keywords: dialysis hemodiafiltration
a clinical study aims to assess the consistency of clinical efficacy in colorectal cancer treatment and drug susceptibility outcomes using a novel drug susceptibility testing method

Conditions: Colorectal Cancer; Organoids

Summary: the study is a real-world observational clinical study. patients diagnosed as colorectal cancer through histopathology were screened and enrolled. before anti-tumor treatment, colonoscopy biopsy tissue specimens, surgical specimens, and malignant pleural effusion or ascites specimens, etc. are collected. the investigators will perform a drug sensitivity testing based on a novel drug susceptibility testing method to test the commonly used anti-tumor treatment regimens. patients were given conventional anti-tumor treatment according to the medical judgment of the doctors. finally, the investigator will evaluate the consistency of clinical efficacy in colorectal cancer treatment and drug susceptibility outcomes.


Eligibility criteria:
inclusion criteria: 1. male or female, aged ≥ 18 and ≤80; 2. patients with colorectal cancer diagnosed by histopathology; 3. patients who need neoadjuvant treatment; adjuvant therapy after radical surgery or palliative treatment; 4. fresh tumor tissue specimens or malignant pleural effusion or ascites can be obtained; 5. patients who sign the informed consent form, and are able to comply with the study period treatment process. exclusion criteria: 1. inability to follow the research protocol; 2. inability to obtain relevant fresh specimens by biopsy/surgery/puncture; 3. concomitant contraindications to chemotherapy; 4. pregnant or lactating women; 5. patients deemed inappropriate by investigators.
ablation in brugada syndrome for the prevention of vf

Conditions: Brugada Syndrome

Summary: this trial aims to develop evidence based curative treatment with optimal net benefit for patients with brugada syndrome.

this trial aims to develop evidence based curative treatment with optimal net benefit for patients with brugada syndrome. since a recent non-randomized pilot study and scarce case reports documented potential clinical benefit of epicardial ablation of fragmented electrograms in the region of the right ventricular outflow tract, patients in this trial will be randomized to continued implanted cardioverter defibrillator therapy (control arm) or ablation of areas of fragmented electrograms in the right ventricular outflow tract plus continued implanted cardioverter defibrillator therapy (intervention arm). a projected 92 patients in each group will be studied.

Eligibility criteria:
inclusion criteria: * the diagnosis of brugada syndrome is based on 2013 hrs/ehra/aphrs consensus document criteria * diagnosed symptomatic brs with an implanted icd within the last 5 years * diagnosed symptomatic brs with an implanted icd longer than 5 years but has at least 1 appropriate shock within the last 5 years * the patient is legally competent, willing and able to undergo the study and signed the informed consent * the patient is willing and able to adhere to the follow-up visit protocol exclusion criteria: * a patient who does not meet inclusion criteria * a patient who has had a previous epicardial ablation * a patient who is pregnant (which would exclude an ablation procedure) * a patient with a co-morbid condition that possesses undue risk of general anesthesia or epicardial ablation * a patient who has a history of radiation therapy on the thorax

Keywords: ventricular arrhythmias aborted cardiac arrest cardiac death
overdiagnosis of thyroid cancer in the marne and ardennes departments of france from 1975 to 2014

Conditions: Papillary Thyroid Cancer

Summary: introduction - incidence of thyroid cancer has increased considerably in france in recent years, but the mortality rate has declined only slightly. part of this increased incidence could be attributable to overdiagnosis. we aimed to estimate the contribution of overdiagnosis to the incidence of papillary thyroid cancer. material and methods. - incidence rates were calculated based on data from the specialised marnes-ardennes thyroid cancer registry, for cancers diagnosed between 1975 and 2014, by age category and by five-year period. the population was divided into two groups according to ptnm classification at diagnosis (i.e. localised or invasive). overdiagnosis was defined as the difference in incidence rates between the invasive cancer and localised cancer groups. this rate was then divided by the incidence rate in the localised cancer group for the most recent period (2010-2014) to obtain the proportion of cancers attributable to overdiagnosis.

introduction - incidence of thyroid cancer has increased considerably in france in recent years, but the mortality rate has declined only slightly. part of this increased incidence could be attributable to overdiagnosis. we aimed to estimate the contribution of overdiagnosis to the incidence of papillary thyroid cancer. material and methods. - we included all subjects living in the marne or ardennes departments of france and who were diagnosed with papillary thyroid cancer between 1975 and 2014. we recorded socio-demographic variables, i.e. age at diagnosis and sex. cancer characteristics were also recorded, namely year of diagnosis, international classification of diseases (icd) 10th revision code associated with the papillary cancer, and the ptnm 2002 status. incidence rates were calculated based on data from the specialised marnes-ardennes thyroid cancer registry, for cancers diagnosed between 1975 and 2014, by age category and by five-year period. the population was divided into two groups according to ptnm classification at diagnosis (i.e. localised or invasive). overdiagnosis was defined as the difference in incidence rates between the invasive cancer and localised cancer groups. this rate was then divided by the incidence rate in the localised cancer group for the most recent period (2010-2014) to obtain the proportion of cancers attributable to overdiagnosis.

Eligibility criteria:
inclusion criteria: * clinical doagnosis of papillary thyroid cancer * living in the marne or ardennes departments of france exclusion criteria: - cancer stage not determined

Keywords: thyroid neoplasms; thyroid gland; ; thyroid gland incidence overdiagnosis
forebrain electroneutral transporters in salt-sensitive hypertension: an mri study

Conditions: Salt-Sensitivity of Blood Pressure

Summary: the overall objective of this project is to identify the key salt-sensing regions of the brain and determine the underlying mechanism of sodium sensing. the investigators will assess how the brain responds to an acute increase of salt in the blood using mri. this will be done during a 30-minute infusion of a saline solution containing 3% salt. one trial will be conducted with a salt sensing channel blocker and one trial without the salt sensing channel blocker. this will help to assess the role of a specific salt sensing channel in the brain. salt sensitivity of bp will be assessed using 7-day dietary feeding where participants will be given food to consume for 7-days. comparisons will be made between salt resistant (no change in blood pressure going from low to high salt diets) and salt sensitive adults (a change in blood pressure going from low to high salt diets). the investigators think the changes in mri will be greater in salt sensitive compared to salt resistant subjects.

the ability of the brain to sense changing sodium levels in the blood is critical in mediating the neurohumoral responses to hypernatremia, however, the mechanisms underlying sodium sensing in humans is poorly understood. the purpose of this study is to identify key sodium-sensing regions of the human brain in middle-aged men and women with high blood pressure and determine if the na-k-2cl co-transporter (nkcc2) mediates the neurohumoral response to acute hypernatremia. the investigators plan on comparing these central sodium responses to acute hypernatremia between salt-sensitive and salt-resistant adults. in this randomized double-blinded crossover study subjects will have a 3% nacl (hypertonic saline) infusion with or without nkcc2 antagonism (furosemide). completion of this project will increase the understanding of blood pressure regulation, which has major public health implications.

Eligibility criteria:
inclusion criteria: * age: \> 40 years or \< 60 years * blood pressure: \> 100/60 mmhg or \< 140/90 mmhg * bmi: \> 18.5 kg/m2 or \< 30 kg/m2 * serum potassium: \> 3.5 mmol/l or \< 5.5 mmol/l * no history of cardiovascular, renal, metabolic, or neurological disease exclusion criteria: * age: \ 60 years * blood pressure: \ 140/90 mmhg * bmi: \ 30 kg/m2 * serum potassium: \ 5.5 mmol/l * abnormal ecg * history of - cardiovascular, cancer, metabolic, respiratory, renal disease * hormone replacement therapy * current tobacco or nicotine use * pregnant or nursing mothers * major brain injury (concussions do not count) * clinically diagnosed psychiatric or neurological disorder * clinically diagnosed anxiety or depression * psychiatric, neurological, anxiety or depression medications * hypertension medications * sulfonamide drug allergy * contra-indications to mri (implants, metal, etc) * claustrophobia
hips screws or (total) hip replacement for undisplaced femoral neck fractures in elderly patients (hipsther)

Conditions: Femoral Neck Fractures; Undisplaced Fracture

Summary: a registerbased rct will investigate whether arthroplasty can decrease the reoperation rate compared to internal fixation for patients with an undisplaced femoral neck fracture (garden i-ii).

the aim of this study is to determine whether the treatment of elderly patients with an undisplaced femoral neck fracture (ufnf) can be improved by decreasing reoperation rates through replacing the hip instead of trying to preserve it. patients ≥75 years with an ufnf will be included and randomized within the swedish fracture register (sfr) platform to internal fixation (screws/pins) or arthroplasty (choice of hemi or total is at the surgeon's discretion). the primary outcome will be a composite variable that combines two variables (reoperations and mortality) into a single variable.

Eligibility criteria:
inclusion criteria: * undisplaced (garden i-ii) femoral neck fracture (within 72h) * treated at participating unit * informed consent * amenable for both treatment options exclusion criteria: * no informed consent * pathological or stress fracture * peri-implant fracture

Keywords: internal fixation hip arthroplasty reoperation rate mortality health economy external validity adverse events
evaluation of safety and efficacy of 0.3 mg/eye macugen in patients with small age-related macular degeneration lesions

Conditions: Macular Degeneration

Summary: to evaluate the efficacy, based on the best-corrected visual acuity (using the etdrs chart), of a 0.3 mg/eye pegaptanib sodium intravitreous injection given every 6 weeks for 54 weeks in patients with exudative age-related macular degeneration and evidence of recent onset, subfoveal and/or juxtafoveal choroidal neovascularization.


Eligibility criteria:
inclusion criteria: * clinical and angiographic evidence of juxtafoveal or subfoveal choroidal neovascularization secondary to amd with a total lesion size of less than 2 mps disc areas * best-corrected visual acuity in the study eye greater than 54 letters (etdrs) * women must be using 2 forms of effective contraception * adequate hematological, renal and liver functions exclusion criteria: * any atrophy or fibrosis; any retinal hemorrhage measuring more than 1 disc area * any extrafoveal choroidal neovascularization * any intraocular surgery or thermal laser to the study eye within 3 months of enrollment * previous or concomitant therapy for amd including pdt with verteporfin (visudyne) or subfoveal/non-foveal thermal laser therapy, transpupillary thermotherapy, external beam radiation, submacular surgery. * presence of other causes of choroidal neovascularization, including pathological myopia, the ocular histoplasmosis syndrome, angioid streaks, choroidal rupture and multifocal choroiditis
alternative non-cross-resistant adjuvant chemotherapy for operable breast cancer non-response to primary chemotherapy

Conditions: Primary Breast Cancer

Summary: the purpose of this phase ⅲ, multi-center, prospective, open-label, randomized,controlled study is to determine whether alternative non-cross-resistant adjuvant chemotherapy can increase distant disease free survival(ddfs) in operable patients non-response to primary chemotherapy.


Eligibility criteria:
inclusion criteria: * female patients, age ≦65 years * biopsy proven lymph node positive, estrogen receptor- positive primary breast cancer * must have completed a 4-cycle neo-adjuvant chemotherapy with a standard regimen(containing anthracycline or paclitaxel) * must have undergone surgery to remove the primary tumor by either a mastectomy or enlarged local excision * postoperative residual positive lymph nodes or g1/g2/g3 of miller \& payne grading system * adequate recovery from recent surgery * no history of other malignancies * no currently uncontrolled diseased or active infection * not pregnant or breast feeding, and on appropriate birth control if of child-bearing potential * adequate cardiovascular function reserve with a myocardial infarction within the past six month * adequate hematologic function with: 1. absolute neutrophil count (anc) ≥1500/mm3 2. platelets ≥100,000/ mm3 3. hemoglobin ≥10 g/dl * adequate hepatic and renal function with: 1. serum bilirubin ≤1.5×unl 2. alkaline phosphatase and alanine aminotransferase (alt) ≤2.5 x uln. (≤5 x uln is acceptable in the setting of hepatic metastasis) 3. bun between 1.7 and 8.3 mmol/l 4. cr between 40 and 110 umol/l * knowledge of the investigational nature of the study and ability to give informed consent * ability and willingness to comply with study procedures. exclusion criteria: * known or suspected distant metastases * concurrent malignancy or history of other malignancy * uncontrolled diseases(e.g., heart failure, myocardial infarction within 6 months, arrhythmia, unstable diabetes, hypercalcemia) or active infection * geographical, social, or psychological problems that would compromise study compliance * known or suspected hypersensitivity to anthracycline or paclitaxel
specified drug use-results survey of betanis tablets

Conditions: Overactive Bladder

Summary: to investigate the effects of mirabegron on the symptoms of glaucoma in overactive bladder (oab) patients with coexisting glaucoma.


Eligibility criteria:
inclusion criteria: * diagnosed as oab and treated with mirabegron * diagnosed as glaucoma (including normal tension glaucoma) * having intraocular pressure measurement conducted more than twice within six months before the start of the mirabegron treatment

Keywords: mirabegron overactive bladder betanis® glaucoma
evaluation of the efficacy, durability, safety, and tolerability of rp-g28 in patients with lactose intolerance

Conditions: Lactose Intolerance

Summary: this is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted in the united states (us) to assess the efficacy of rp-g28 compared to placebo on symptom reduction related to lactose intolerance.


Eligibility criteria:
inclusion criteria: * patient is 18-75 years of age, inclusive, at screening; * intolerance to milk and other dairy products; * patient agrees to refrain from all other treatments and products used for lactose intolerance, to follow diet modifications required during periods of the study that include abstinence from all dairy in some periods and consuming dairy in other periods; * patient meets the defined minimum lactose intolerance symptom composite score; and * patient has positive hydrogen breath test (hbt) results for lactase deficiency. exclusion criteria: * patient has a disorder associated with abnormal gastrointestinal motility such as gastroparesis (from any cause), amyloidosis, neuromuscular diseases (including parkinson's disease), collagen vascular diseases, uremia, or malnutrition; * patient has undergone bowel preparation for endoscopic or radiologic investigation within 4 weeks of screening (example, colonoscopy preparation); * patient has a history of surgery that alters the normal function of the gastrointestinal tract including, but not limited to: fundoplication, gastrointestinal bypass surgery, bariatric surgery, gastric banding, colostomy, vagotomy, pyloroplasty, colectomy or other surgery for crohn's disease or ulcerative colitis; and * patient has received antibiotic treatment, or had a high colonic enema, colonic irrigation, colonic hydrotherapy, or colonic cleaning within 30 days prior to or during screening.

Keywords: lactose intolerance
minimal invasive surgery in total hip arthroplasty patients; short- and long term results

Conditions: Hip Osteoarthritis

Summary: the aim of the present study is to explore the most efficient surgical approach in total hip replacement in short and long term when concerning strength, functionality and postoperative complications. the objective is to register muscular strength, hip joint functionality/mobilisation and complications after total hip arthroplasty (tha) performed by the direct lateral approach (dla), the posterior approach (pa) and the anterior approach (aa). the latter is a modified smith-petersen approach which follows the principles of minimally invasive surgery (mis). the primary working hypothesis is that due to a minimal dissection and reduced trauma in the muscles, patients will tolerate early hospital discharge better after the aa than the pa and the dla. patients in the aa group are also thought to be more active and maintain muscular strength and hip joint functionality/mobilisation better than patients in the lateral group.

with total hip replacement surgery, the orthopaedic surgeon's aim is not only pain relief for the patient, but also restoration of hip joint biomechanics resulting in a minimal functional deficit and maximal longevity of the implant. it is not exceptional that these patients still experience mild to moderate long-term impairments postoperatively. these impairments include pain, muscle weakness of the hip abductors, contracture of the hip, gait disorders, as well as weakness of hip extensors and flexors. these problems may in turn lead to complications such as joint instability and loosening of the implant. mis is defined as a surgical approach performed through a short skin and muscle incision to avoid injury to muscles and tendons. following minimally invasive approach reduced muscle trauma has been found. moreover clinical outcome improved, as the gluteus medius muscle can be spared more successfully. however, it is debated whether or not the overall results of mis are superior, or even as good as the traditional hip replacement surgery in terms of component placing and time to revision of the prosthesis.

Eligibility criteria:
inclusion criteria: * patients scheduled for tha * diagnosis of primary osteoarthritis as the main cause for elective tha * american society of anesthesiologists (asa) score i, ii, and stable iii exclusion criteria: * musculoskeletal diseases * current heart/pulmonary- or malignant diseases likely to influence the physical testing performance.

Keywords: arthroplasty, replacement, hip surgical procedures, operative surgical procedures, minimally invasive